Monogram Biosciences, Inc.

South San Francisco, CA 94080

SBIR Award Summary

Total Number of Awards 29
Total Value of Awards $14.9MM
First Award Date 05/01/01
Most Recent Award Date 08/01/08

Key Personnel

Last Name Name Awards Contact
Petropoulos Christos J Petropoulos 16
Parkin Neil T Parkin 6
Chappey Colombe Chappey 5
Bates Michael P Bates 2

29 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 08/01/08 - 07/31/10

DESCRIPTION (provided by applicant): Currently approved drugs inhibit HIV-1 replication by interfering with the enzymatic activities of either protease (PR), reverse transcriptase (RT), or with the entry process. The ability of HIV to rapidly evolve drug resistance to approved PR, RT and entry inhibitors, together with toxicity problems of curre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 07/01/08 - 06/30/09

DESCRIPTION (provided by applicant): Experts agree that an effective vaccine against HIV infection will require the induction of potent and broad neutralizing antibody responses. Both the development and clinical evaluation of vaccine candidates requires a sensitive, reproducible and high throughput HIV antibody neutralization assay. Sensitivit...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 07/01/08 - 06/30/09

DESCRIPTION (provided by applicant): In areas of the world most negatively impacted by the HIV epidemic, healthcare economics are unable to support complex diagnostic testing such as drug resistance phenotyping. Consequently, there is a pressing need to develop bioinformatic solutions that will enable predictions of drug activity and treatment ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 08/01/07 - 07/31/08

DESCRIPTION (provided by applicant): Currently approved drugs inhibit HIV-1 replication by interfering with the enzymatic activities of either protease (PR), reverse transcriptase (RT), or with the entry process. The ability of HIV to rapidly evolve drug resistance to approved PR, RT and entry inhibitors, together with toxicity problems of curre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 07/15/07 - 06/30/08

DESCRIPTION (provided by applicant): In areas of the world most negatively impacted by the HIV epidemic, healthcare economics are unable to support complex diagnostic testing such as drug resistance phenotyping. Consequently, there is a pressing need to develop bioinformatic solutions that will enable predictions of drug activity and treatment ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 07/01/07 - 06/30/08

DESCRIPTION (provided by applicant): Experts agree that an effective vaccine against HIV infection will require the induction of potent and broad neutralizing antibody responses. Both the development and clinical evaluation of vaccine candidates requires a sensitive, reproducible and high throughput HIV antibody neutralization assay. Sensitivit...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 08/15/06 - 07/31/07

DESCRIPTION (provided by applicant): Currently approved drugs inhibit HIV-1 replication by interfering with the enzymatic activities of either protease (PR), reverse transcriptase (RT), or with the entry process. The ability of HIV to rapidly evolve drug resistance to approved PR, RT and entry inhibitors, together with toxicity problems of curre...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-27
Budget: 05/01/06 - 04/30/08

Despite the remarkable success of highly active antiretroviral therapy (HAART), prolonged administration of antiietroviral agents is commonly associated with the emergence of resistant viruses and subsequent treatment failure. In response to the need for additional antiretroviral agents with non-overlapping resistance profiles, the first entry i...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/06 - 02/28/07

DESCRIPTION (provided by applicant): Recent strides in HIV-1 vaccine research have begun to define the roles of cellular and humoral immune responses and have renewed optimism that an effective prophylactic vaccine can be developed (Ho and Huang, 2002). It is anticipated that several vaccine candidates will be ready for large-scale evaluations i...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/06 - 02/28/09

DESCRIPTION (provided by applicant): Phenotypic and genotypic drug resistance assays are used routinely for management of treatment experienced, HIV-1 infected patients in North America and Western Europe. As anti-retroviral therapy becomes a reality in resource-poor countries, the need for resistance testing to monitor the emergence of drug res...

Load More